Researchers examine how the COVID-19 pandemic affected cancer diagnosis rates between 2021 and 2020.
ChromaDex wins orphan designation for rare ataxia drug – Pharmaceutical Technology
Ataxia telangiectasia is a rare, inherited, progressive childhood disorder for which symptoms manifest neurologically and immunologically. Chromadex is developing a candidate to treat ataxia telangiectasia.